Original Article
Trial of Calcium to Prevent Preeclampsia
N Engl J Med 1997; 337:69-77July 10, 1997
- Abstract
Background
Previous trials have suggested that calcium supplementation during pregnancy may reduce the risk of preeclampsia. However, differences in study design and a low dietary calcium intake in the populations studied limit acceptance of the data.
Methods
We randomly assigned 4589 healthy nulliparous women who were 13 to 21 weeks pregnant to receive daily treatment with either 2 g of elemental calcium or placebo for the remainder of their pregnancies. Surveillance for preeclampsia was conducted by personnel unaware of treatment-group assignments, using standardized measurements of blood pressure and urinary protein excretion at uniformly scheduled prenatal visits, protocols for monitoring these measurements during the hospitalization for delivery, and reviews of medical records of unscheduled outpatient visits and all hospitalizations.
Results
Calcium supplementation did not significantly reduce the incidence or severity of preeclampsia or delay its onset. Preeclampsia occurred in 158 of the 2295 women in the calcium group (6.9 percent) and 168 of the 2294 women in the placebo group (7.3 percent) (relative risk, 0.94; 95 percent confidence interval, 0.76 to 1.16). There were no significant differences between the two groups in the prevalence of pregnancy-associated hypertension without preeclampsia (15.3 percent vs. 17.3 percent) or of all hypertensive disorders (22.2 percent vs. 24.6 percent). The mean systolic and diastolic blood pressures during pregnancy were similar in both groups. Calcium did not reduce the numbers of preterm deliveries, small-for-gestational-age births, or fetal and neonatal deaths; nor did it increase urolithiasis during pregnancy.
Conclusions
Calcium supplementation during pregnancy did not prevent preeclampsia, pregnancy-associated hypertension, or adverse perinatal outcomes in healthy nulliparous women. (N Engl J Med 1997;337:69 -76.)
Media in This Article
Figure 1
Effect of Calcium Supplementation on the Incidence of Preeclampsia.Figure 2
Mean (±SE) Diastolic and Systolic Blood Pressures at Scheduled Clinic Visits in the Calcium and Placebo Groups According to the Week of Gestation.Article Activity
- Article
About 5 percent of all pregnant women have preeclampsia, defined as hypertension and proteinuria beginning during the second half of gestation.1 Preeclampsia is a leading cause of maternal death throughout the world and is accompanied by substantial perinatal morbidity and mortality.2 The search for an effective preventive therapy has therefore been a major focus of obstetrical investigation.
The results of 13 clinical trials3-15 and several meta-analyses16-20 have suggested that calcium supplementation reduces the incidence of preeclampsia. Critical review of these reports, however, reveals important differences in study design that limit acceptance of these past trials.17,19,21,22 Many were conducted in countries where, unlike the United States, the usual diet contains little calcium.3-5,7-9,11,14 In response to the need for a more definitive evaluation of calcium supplementation to prevent preeclampsia in the United States, the Calcium for Preeclampsia Prevention (CPEP) trial was undertaken at five U.S. medical centers.
Methods
Subjects
The study protocol was approved by the institutional review boards at the five participating medical centers, and all the women gave written informed consent.
We assembled the potential study cohort by screening nulliparous women who were 11 to 21 weeks pregnant to exclude those who were taking medications or had obstetrical conditions, preexisting diseases, or personal characteristics that could markedly influence the study end points, the absorption or metabolism of calcium, any risk associated with calcium supplementation, or compliance. To minimize the possibility of urolithiasis, we excluded women with elevated serum concentrations of creatinine (>1.0 mg per deciliter [88.4 μmol per liter]) or calcium (>10.6 mg per deciliter [2.6 mmol per liter]), those with renal disease, hematuria, or a history of urolithiasis in themselves or a first-degree relative, and those who reported frequent use of calcium supplements or antacids. The eligible women then underwent a single-blind test of compliance with medication, during which they were asked to take two placebo tablets with their morning and evening meals for 6 to 14 days. Women were enrolled in the trial if they took at least 75 percent of the placebo tablets during the test, if both before and after the test their blood pressure was 134/84 mm Hg or less and a dipstick test for urinary protein was negative or showed only a trace, and if they were 13 to 21 weeks pregnant as determined by ultrasonography or by menstrual dates confirmed by ultrasonography. A detailed description of the screening and selection procedures, including a complete list of exclusion criteria, has been published previously.21
Of 11,959 nulliparous women screened, 5703 were excluded before the compliance test. Only about one fifth of the exclusions were for medical reasons, most often a personal or family history of urolithiasis. An additional 1667 women were excluded after the compliance test. The remaining 4589 women were enrolled in the double-blind study of calcium supplementation or placebo. Women began treatment on the day of enrollment, which was before the 22nd week of gestation.
Additional Base-Line Evaluations
To determine whether calcium supplementation would be more beneficial to women with lower dietary calcium intake or urinary calcium excretion at base line, dietary intake was estimated by means of a 24-hour dietary-recall report obtained by a specially trained dietician or research nurse and 24-hour and first morning urine specimens were collected for calcium and creatinine measurements.
Medications
The chewable study tablets, consisting largely of cornstarch and confectioner's sugar, were packaged individually in blister packs. The calcium tablets also contained 500 mg of elemental calcium as calcium carbonate. Fifty tablets each of calcium and placebo were selected at random for analysis. The mean calcium content of the calcium tablets was 485 mg (range, 453 to 539). None of the placebo tablets contained calcium (<30 mg). The women were instructed to take two tablets with each of their morning and evening meals until delivery, diagnosis of preeclampsia, or suspicion of urolithiasis. They were also asked to drink at least six glasses of fluid per day.
In addition, the women were given a daily prenatal supplement (Mission Prenatal) containing 50 mg of elemental calcium, 30 mg of iron, 400 units of vitamin D2, and other vitamins.21 Acetaminophen tablets (Tylenol) and an antacid not containing calcium (Mylanta) were dispensed as needed, but the women were asked not to take other supplements, analgesics, or antacids.
Randomization
Packages of study tablets were prepared and numbered by the pharmaceutical manufacturer according to a computer-generated simple randomization sequence developed by the study statisticians. The packages were then shipped to the medical centers. On enrollment, each woman was assigned the next numbered package of medication at that center.
Surveillance for Hypertension and Proteinuria
We conducted surveillance for hypertension and proteinuria using standardized measurements of blood pressure and urinary protein excretion at uniformly scheduled clinic visits, protocols for monitoring these measurements during the hospitalization for delivery, and reviews of the medical records of unscheduled outpatient visits and all hospitalizations until 24 hours post partum.
The women were to be examined by trained staff members every 4 weeks through the 29th week of gestation, every 2 weeks through the 35th week, and weekly thereafter. Blood pressure was measured with the subject in the sitting position by a certified examiner using a standard mercury sphygmomanometer according to a published protocol21; two measurements were taken at least one minute apart, and the results were averaged. Diastolic blood pressure was determined by using the fifth Korotkoff sound unless a measurement was zero, in which case the fourth sound was used. Voided urine was collected for the measurement of protein by dipstick. Proteinuria of >1+ (300 mg per liter) was confirmed by testing a clean-catch, midstream sample.
Surveillance for Urolithiasis
At each clinic visit, a dipstick test for hematuria was performed and the women were asked about flank and groin pain and symptoms of urinary tract infection. If urolithiasis was suspected or hematuria confirmed (except if caused by a urinary tract infection that responded to therapy), renal ultrasonography was performed.21
Assessment of Compliance
The women were asked to return all the dispensed blister packs at every study visit and at the time of hospitalization for delivery. Compliance was computed by dividing the number of tablets removed from the returned blister packs by the total number of prescribed tablets.
Definitions of Outcomes
Pregnancy-associated hypertension was defined as a diastolic blood pressure of 90 mm Hg or greater on two occasions 4 to 168 hours (one week) apart. Severe pregnancy-associated hypertension was defined as a diastolic blood pressure of 110 mm Hg or greater on two occasions 4 to 168 hours apart, or on one occasion if the woman had received antihypertensive therapy. Severe pregnancy-associated hypertension was also diagnosed when pregnancy-associated hypertension was complicated by otherwise unexplained oliguria (<400 ml of urine per 24 hours), pulmonary edema, or thrombocytopenia (two platelet counts <100,000 per cubic millimeter).
Pregnancy-associated proteinuria was defined as any of the following: >300 mg of protein in a 24-hour urine sample, two urine specimens obtained 4 to 168 hours apart containing >1+ protein as measured by dipstick, or a single urine specimen with a ratio of protein to creatinine (both measured in milligrams) of >0.35 or containing >2+ protein as measured by dipstick. Catheterized specimens were required after membrane rupture or in the presence of vaginitis. Severe pregnancy-associated proteinuria was diagnosed if a 24-hour urine sample contained >3.5 g protein or if two urine specimens obtained 4 to 168 hours apart contained >3+ protein (3000 mg per liter) as measured by dipstick. All other pregnancy-associated proteinuria was termed mild.
Preeclampsia was defined as pregnancy-associated hypertension and pregnancy-associated proteinuria occurring within seven days of each other. This period was selected to avoid the diagnosis of preeclampsia in women with hypertension at term but proteinuria (often from urinary tract infections) at a time remote from term. Eclampsia was diagnosed when a woman with pregnancy-associated hypertension had a seizure without any other known cause. The HELLP syndrome (hemolysis, elevated liver enzymes, and low platelet counts) was defined as the presence of pregnancy-associated hypertension with two or more platelet counts of less than 100,000 per cubic millimeter, a serum aspartate aminotransferase concentration >70 U per liter, and a serum lactate dehydrogenase concentration >600 U per liter, a serum total bilirubin concentration >1.2 mg per deciliter (20.5 μmol per liter), or a peripheral-blood smear with nucleated red cells or schistocytes. Severe preeclampsia was defined as preeclampsia with either severe pregnancy-associated hypertension or severe pregnancy-associated proteinuria, or as eclampsia or the HELLP syndrome with or without proteinuria.
Infants small for gestational age were defined as those whose birth weights were below the 10th percentile according to the standards of Brenner et al.23 Neonatal hypocalcemia was defined as serum total calcium of less than 8.0 mg per deciliter (2.0 mmol per liter), or less than 7.0 mg per deciliter (1.7 mmol per liter) for infants of less than 37 weeks' gestation.
Urolithiasis was confirmed if a stone was recovered or seen on renal ultrasonography, radiography, computed tomography, or magnetic resonance imaging. Urolithiasis was suspected if the woman had hematuria and severe flank pain in the absence of pyuria, fever, and leukocytosis.
Nested Case–Control Studies of Urinary Calcium Excretion
Urinary calcium was measured by flame atomic absorption spectrophotometry.24 Urinary creatinine was measured in a modified kinetic Jaffé reaction.25,26
To determine whether calcium supplementation provided a greater benefit to women with lower urinary calcium excretion, nested case–control studies of base-line urinary calcium excretion were conducted in women with adequate first morning and 24-hour urine specimens. For each woman with preeclampsia, four women without hypertensive or proteinuric end points were randomly selected, matched for clinical center and the presence of a 24-hour urine sample that appeared to be adequate; an adequate sample was defined initially as one that had no visible blood and, for 24-hour specimens, no reported missing voids and a volume of at least 400 ml. Creatinine was then measured in the urine sample; if the value was 15 mg (132 μmol) or more per kilogram of body weight, the sample was confirmed as being adequate.
Statistical Analysis
All the women randomly assigned to treatment were included in the primary analysis regardless of their follow-up status or compliance with treatment. Comparisons between the calcium and placebo groups for outcomes with discrete categories were performed by using a two-sided Mantel–Haenszel or Fisher's exact test at the 0.05 level. Risk ratios and 95 percent confidence intervals were estimated by the Mantel–Haenszel procedure.27
Differences in blood pressure between the groups during weeks 20 to 40 of gestation were evaluated by a repeated-measures analysis after adjustment for base-line differences and the correlation of observations of the same woman.28 Differences in the length of time until the onset of preeclampsia were assessed by life-table methods and the log-rank test.29
Results
Of 4589 women enrolled in the trial, 2295 were assigned to receive calcium and 2294 to receive placebo. The demographic and clinical characteristics of the women in the two groups were similar (Table 1Table 1
Characteristics of the Nulliparous Pregnant Women at Enrollment, According to Treatment Group.). Two hundred fifty-three women (5.5 percent) were lost to follow-up: 132 in the calcium group and 121 in the placebo group.Compliance
The numbers of completed and missed study visits, unscheduled outpatient visits, and hospitalizations were similar in the two groups. Compliance with medication averaged 64 percent in the calcium group and 67 percent in the placebo group (P<0.001). The median daily consumption of calcium from all sources in the calcium group (base-line dietary intake plus supplemental calcium actually taken) was more than twice that in the placebo group (2369 vs. 982 mg).
Incidence of Hypertensive Disorders and Proteinuria
The frequency of hypertensive disorders and proteinuria in each treatment group is shown in Table 2Table 2
Incidence of Hypertensive Disorders and Proteinuria during Pregnancy, According to Treatment Group.. The incidence of preeclampsia was 6.9 percent in the calcium group and 7.3 percent in the placebo group (relative risk, 0.94; 95 percent confidence interval, 0.76 to 1.16). There were no statistically significant differences between the groups in the incidence of pregnancy-associated hypertension without preeclampsia, pregnancy-associated proteinuria without hypertension, or all hypertensive disorders. Moreover, significant differences between the treatment groups were not detected when preeclampsia and pregnancy-associated hypertension without preeclampsia were examined within categories of severity (Table 2), at individual medical centers, or among white Hispanic, white non-Hispanic, or black (including black Hispanic) women (data not shown). The HELLP syndrome and eclampsia were not less frequent in the calcium group; there were seven and four cases, respectively, as compared with two and four in the placebo group.The relative risks of preeclampsia (Figure 1Figure 1
Effect of Calcium Supplementation on the Incidence of Preeclampsia.) and of pregnancy-associated hypertension without preeclampsia (data not shown) did not differ according to the quintile of base-line dietary calcium intake, the level of compliance with medication, or the age stratum, and the results of tests for interaction between the treatment group and each of these risk factors were not significant. Similarly, stratified analyses did not indicate a greater benefit from calcium supplementation with shorter duration of gestation at enrollment. Odds ratios for the occurrence of preeclampsia in the treatment groups did not differ according to whether the woman's base-line 24-hour urinary calcium excretion or ratio of urinary calcium to creatinine in the first morning urine was above or below the median (212 mg [5.3 mmol] or a ratio of 0.153 with measurements in milligrams [0.4327 with measurements in millimoles]) or above or below the median ratio of a previous study (0.22 with measurements in milligrams [0.62 with measurements in millimoles]).11 There was no significant difference between treatment groups in duration of gestation at the onset of preeclampsia.Blood pressures at scheduled clinic visits are shown according to the duration of gestation in Figure 2Figure 2
Mean (±SE) Diastolic and Systolic Blood Pressures at Scheduled Clinic Visits in the Calcium and Placebo Groups According to the Week of Gestation.. The mean systolic blood pressure during weeks 20 to 40 of gestation was slightly, but not significantly, lower in the calcium group (by 0.3 mm Hg; 95 percent confidence interval, 0.7 mm Hg lower to 0.1 mm Hg higher). The diastolic pressure, however, was minimally higher in the calcium group (by 0.03 mm Hg; 95 percent confidence interval, 0.3 mm Hg lower to 0.4 mm Hg higher).Obstetrical Complications and Perinatal Outcomes
There were no significant differences between the groups in important obstetrical complications (Table 3Table 3
Obstetrical Complications According to Treatment Group.) or perinatal outcomes (Table 4Table 4
Perinatal Outcome According to Treatment Group.). Neither urolithiasis during pregnancy nor neonatal hypocalcemia was significantly increased in the calcium group.Discussion
In this study, supplementation with 2 g of calcium daily did not reduce the incidence or severity of preeclampsia or delay its onset, nor did it reduce the incidence of pregnancy-associated hypertension without preeclampsia. When the analyses were stratified according to compliance, there was no effect on preeclampsia or on pregnancy-associated hypertension without preeclampsia, even among the women who were most compliant with treatment. Blood pressures during pregnancy were similar in the treatment groups, as was consistent with the absence of any effect on preeclampsia or pregnancy-associated hypertension.
Calcium supplementation might be expected to be of greater benefit to women with lower intakes of dietary calcium. In one trial, a low ratio of urinary calcium to creatinine in the first morning urine at the time of enrollment, which could reflect a low dietary intake, was a predictor of benefit.11 However, we detected no benefit in women with low base-line 24-hour urinary calcium excretion or low ratios of urinary calcium to creatinine in the first morning urine. Nor was there any benefit among women whose base-line dietary calcium intakes were in the lowest quintile and whose median daily intake of 422 mg was similar to or less than that reported for women in many developing countries.7,8,11 The biologic demand for calcium during pregnancy is greatest during adolescence, when calcium is needed for both maternal and fetal growth. The youngest women, therefore, might be expected to derive the greatest benefit from calcium supplementation. Nevertheless, we found no benefit in 12-to-16-year-olds.
It has been suggested that calcium supplementation might also reduce the incidence of preterm deliveries, cesarean deliveries, births of infants small for their gestational ages, and perinatal deaths.18,20 These beneficial consequences would be due in part to the prevention of preeclampsia and pregnancy-associated hypertension but could theoretically also result from direct effects on uterine smooth muscle to reduce contractility and prevent preterm labor.10 We found no reduction in obstetrical complications or adverse perinatal outcomes among women assigned to receive calcium supplementation.
Urinary calcium excretion rises in normal pregnant women because of increased intestinal absorption.30 The addition of 2 g of calcium to the diet, therefore, could further increase urinary calcium excretion and thus the risk of renal calculi.31 We did not find an increase in renal calculi among the women who received calcium supplements, although women considered at increased risk at base line were excluded from the study. Another potential complication of maternal calcium supplementation is neonatal hypocalcemia, which may be caused by the suppression of infant parathyroid secretion.32 Although systematic surveillance for neonatal hypocalcemia was not conducted, the proportions of reported cases did not differ between the treatment groups.
The results of this trial contradict those of published meta-analyses of calcium supplementation in pregnancy,16-20 including the most recent, which found an important reduction in systolic and diastolic blood pressure and preeclampsia.20 The number of women in our study was more than twice that in the entire recent meta-analysis, and the dose of calcium administered equaled the highest in previous studies. Most previous studies, moreover, lacked a placebo group3-7,12,14,15 or were conducted in women selected because they were at high risk for preeclampsia.9,13 One study is difficult to accept because of the elevated rate of preeclampsia (23 percent) in the placebo group and the unlikely observation that all the women in whom hypertension developed also had proteinuria.8 Another trial cited in two preeclampsia meta-analyses18,20 did not distinguish preeclampsia from gestational hypertension.33 The outcomes with respect to preeclampsia and gestational hypertension in the remaining two studies10,11 were statistically consistent with those in our trial. Our experience heightens our concern about the proper use of meta-analysis.34,35 A large effect indicated by a meta-analysis of relatively small trials has not always been confirmed by subsequent large trials.36 Meta-analyses cannot substitute for large, well-conducted clinical trials.
In summary, supplementation with 2 g of calcium per day did not reduce the incidence of preeclampsia, pregnancy-associated hypertension, or important maternal and perinatal complications of pregnancy in nulliparous women. Moreover, supplementation did not appear to prevent adverse pregnancy outcomes in adolescents or in women with low base-line dietary calcium intakes or urinary calcium excretion. Our results do not support the use of calcium supplementation to prevent preeclampsia in healthy nulliparous women.
Supported by the National Institute of Child Health and Human Development under contracts N01-HD-1-3121 through 3126, N01-HD-2-3154, and N01-HD-5-3246, with co-funding from the National Heart, Lung, and Blood Institute.
We are indebted to the members of the Calcium for Preeclampsia Prevention (CPEP) Data Safety and Monitoring Board: Marshall Lindheimer, M.D., Colin Begg, Ph.D., Thomas Chalmers, M.D. (deceased), Maurice Druzin, M.D., Robert Sokol, M.D., and Reginald Tsang, M.B., B.S.; to the CPEP Clinic Coordinators: Lynn Barabach, R.N., Brenda Stofan, R.N., Veronica Dorato, R.N., Teresa Carr, R.N., and Karen McCracken, R.N.; to Heinz Berendes, M.D., Jose Rigau-Perez, M.D., and Jose Villar, M.D., without whom this trial would not have been undertaken; to Donald Stablein, Ph.D., James Knoke, Ph.D., Ms. Donna Brown, Ms. Kate Tomlin, Ms. Martine Thompson, Mr. Warren Pendleton, Robert Kiwi, M.D., Brian Mercer, M.D., Carlene Grim, R.N., Margo Woods, D.Sc., Ms. Ann LaBrode, James Leef, Ph.D., Ms. Nichole Nelson, Ms. Lynn Salo, and Mr. Harvey Shifrin for their assistance; to Glen Hortin, M.D., and Tsunenobu Tamura, M.D., for the analyses of urine calcium and creatinine and of the calcium content of the study tablets; to the Department of Obstetrics and Gynecology at the Lovelace Medical Center for the recruitment and follow-up of CPEP patients; to SmithKline Beecham Consumer Brands for the study tablets; to McNeil Consumer Products Co. for the acetaminophen tablets; to Mission Pharmacal Co. for supplying Mission Prenatal supplements; to Johnson & Johnson–Merck for providing Mylanta; and to Miles, Inc., for providing Ames reagent strips.
Source Information
From the Division of Epidemiology, Statistics, and Prevention Research, National Institute of Child Health and Human Development, Bethesda, Md. (R.J.L., R.D., E.G.R., J.D.C.); the Department of Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham (J.C.H.); the Department of Obstetrics and Gynecology, University of New Mexico Health Sciences Center, Albuquerque (L.B.C.); the Department of Obstetrics and Gynecology, University of Tennessee College of Medicine, Memphis (B.M.S.); the Department of Obstetrics and Gynecology, MetroHealth Medical Center, Case Western Reserve University, Cleveland (P.M.C.); the Department of Medicine, Oregon Health Sciences University, Portland (C.D.M.); the Emmes Corporation, Potomac, Md. (J.R.E.); Family Health International, Research Triangle Park, N.C. (E.G.R.); and the Division of Epidemiology and Clinical Applications, National Heart, Lung, and Blood Institute, Bethesda, Md. (D.E.B., J.A.C.).
Address reprint requests to Dr. Levine at the Division of Epidemiology, Statistics, and Prevention Research, National Institute of Child Health and Human Development, National Institutes of Health, Bldg. 6100, Rm. 7B03, Bethesda, MD 20892-7510.
Other authors were Marian G. Ewell, Sc.D. (Emmes Corp., Potomac, Md.), Steven A. Friedman, M.D. (University of Tennessee College of Medicine, Memphis), Robert L. Goldenberg, M.D. (University of Alabama at Birmingham), Sig-Linda Jacobson, M.D. (Oregon Health Sciences University, Portland), Gary M. Joffe, M.D. (University of New Mexico Health Sciences Center, Albuquerque), Mark A. Klebanoff, M.D. (National Institute of Child Health and Human Development, Bethesda, Md.), and Alice S. Petrulis, M.D. (MetroHealth Medical Center, Cleveland).
- References
References
1
Hypertensive disorders in pregnancy. In: Cunningham FG, MacDonald PC, Gant NF. Williams obstetrics. 18th ed. Norwalk, Conn.: Appleton & Lange, 1989:653-94.
2
National High Blood Pressure Education Program Working Group report on high blood pressure in pregnancy
Web of Science3
Theobald GW . Effect of calcium and vitamins A and D on incidence of pregnancy toxaemia. Lancet 1937;1:1397-1399
CrossRef4
Nutrition of expectant and nursing mothers: interim report of the People's League of HealthLancet 1942;2:10-12
5
Chaudhuri SK . Calcium deficiency and toxaemia of pregnancy. J Obstet Gynaecol India 1969;19:313-3166
Montanaro D ,Boscutti G ,Antonucci F , et al. Prevention of pregnancy-induced hypertension (P.I.H.) and preeclampsia (P.E.) by oral calcium supplementation: preliminary results. Miner Metab Res Italy 1986;7:121-1247
Marya RK ,Rathee S ,Manrow M . Effect of calcium and vitamin D supplementation on toxaemia of pregnancy. Gynecol Obstet Invest 1987;24:38-42
CrossRef | Web of Science | Medline8
Lopez-Jaramillo P ,Narvaez M ,Weigel RM ,Yepez R . Calcium supplementation reduces the risk of pregnancy-induced hypertension in an Andes population. Br J Obstet Gynaecol 1989;96:648-655
CrossRef | Medline9
Lopez-Jaramillo P ,Narvaez M ,Felix C ,Lopez A . Dietary calcium supplementation and prevention of pregnancy hypertension. Lancet 1990;335:293-293
CrossRef | Web of Science | Medline10
Villar J ,Repke JT . Calcium supplementation during pregnancy may reduce preterm delivery in high-risk populations. Am J Obstet Gynecol 1990;163:1124-1131
Web of Science | Medline11
Belizan JM ,Villar J ,Gonzalez L ,Campodonico L ,Bergel E . Calcium supplementation to prevent hypertensive disorders of pregnancy. N Engl J Med 1991;325:1399-1405
Full Text | Web of Science | Medline12
Ito M ,Koyama H ,Ohshige A ,Maeda T ,Yoshimura T ,Okamura H . Prevention of preeclampsia with calcium supplementation and vitamin D3 in an antenatal protocol. Int J Gynaecol Obstet 1994;47:115-120
CrossRef | Web of Science | Medline13
Sanchez-Ramos L ,Briones DK ,Kaunitz AM ,Delvalle GO ,Gaudier FL ,Walker CD . Prevention of pregnancy-induced hypertension by calcium supplementation in angiotensin II-sensitive patients. Obstet Gynecol 1994;84:349-353
Web of Science | Medline14
Cong K ,Chi S ,Liu G . Calcium and pregnancy induced hypertension. Chung Hua Fu Chan Ko Tsa Chih 1993;28:657-65915
Suzuki Y, Itoh Y, Hayashi Y, et al. Calcium supplementation to prevent gestational hypertension. In: Abstract book: 10th World Congress: International Society for the Study of Hypertension in Pregnancy, Seattle, August 4–8, 1996:152. abstract.
16
Duley L. Prevention and treatment of pre-eclampsia. Oxford Database of Perinatal Trials Newsletter. February 1991:2-4.
17
Levine RJ ,Raymond E ,DerSimonian R ,Clemens JD . Preeclampsia prevention with calcium supplementation. Clin Appl Nutr 1992;2:30-3818
Carroli G ,Duley L ,Belizan JM ,Villar J . Calcium supplementation during pregnancy: a systematic review of randomised controlled trials. Br J Obstet Gynaecol 1994;101:753-758
CrossRef | Medline19
DerSimonian R . Meta-analysis in the design and monitoring of clinical trials. Stat Med 1996;15:1237-1248
CrossRef | Web of Science | Medline20
Bucher HC ,Guyatt GH ,Cook RJ , et al. Effect of calcium supplementation on pregnancy-induced hypertension and preeclampsia: a meta-analysis of randomized controlled trials. JAMA 1996;275:1113-1117
CrossRef | Web of Science | Medline21
Levine RJ ,Esterlitz JR ,Raymond EG , et al. Trial of Calcium for Preeclampsia Prevention (CPEP): rationale, design, and methods. Control Clin Trials 1996;17:442-469
CrossRef | Medline22
Levine RJ ,DerSimonian R . Effects of calcium supplementation on pregnancy-induced hypertension. JAMA 1996;276:1387-1387
CrossRef | Web of Science | Medline23
Brenner WE ,Edelman DA ,Hendricks CH . A standard of fetal growth for the United States of America. Am J Obstet Gynecol 1976;126:555-564
Web of Science | Medline24
Trudeau DL ,Freier EF . Determination of calcium in urine and serum by atomic absorption spectrophotometry (AAS). Clin Chem 1967;13:101-114
Web of Science | Medline25
Hoffman RJ ,Feld RD . A modified procedure for creatinine (CRT) which eliminates bilirubin (BILT) interference on the Hitachi 737. Clin Chem 1988;34:1313-1313 abstract.
Web of Science26
Swanson AF, Swartzentruber M, Nolen PA, Crawford K, Sine HE. Multicenter evaluation of the Boehringer Mannheim compensated, rate-blanked creatinine/Jaffe application on BM/Hitachi systems. In: Advances in clinical diagnostics. Indianapolis: Boehringer Mannheim, 1993:3-11.
27
Kleinbaum DG, Kupper LL, Morgenstern H. Epidemiologic research: principles and quantitative methods. New York: Van Nostrand Reinhold, 1982:340-55.
28
Diggle PJ, Liang K-Y, Zeger SL. Analysis of longitudinal data. Oxford, England: Oxford University Press, 1994.
29
Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: John Wiley, 1980.
30
Heaney RP ,Skillman TG . Calcium metabolism in normal human pregnancy. J Clin Endocrinol Metab 1971;33:661-670
CrossRef | Web of Science | Medline31
Maikranz P ,Holley JL ,Parks JH ,Lindheimer MD ,Nakagawa Y ,Coe FL . Gestational hypercalciuria causes pathological urine calcium oxalate supersaturations. Kidney Int 1989;36:108-113
CrossRef | Web of Science | Medline32
Calcium and hypocalcemia. In: Klaus MH, Fanaroff AA, eds. Care of the high-risk neonate. 3rd ed. Philadelphia: W.B. Saunders, 1986:227-31.
33
Villar J ,Repke J ,Belizan JM ,Pareja G . Calcium supplementation reduces blood pressure during pregnancy: results of a randomized controlled clinical trial. Obstet Gynecol 1987;70:317-322
Web of Science | Medline34
Wachter KW . Disturbed by meta-analysis? Science 1988;241:1407-1408
CrossRef | Web of Science | Medline35
Baxter GF ,Sumeray MS ,Walker JM . Infarct size and magnesium: insights into LIMIT-2 and ISIS-4 from experimental studies. Lancet 1996;348:1424-1426
CrossRef | Web of Science | Medline36
Borzak S ,Ridker PM . Discordance between meta-analyses and large-scale randomized, controlled trials: examples from the management of acute myocardial infarction. Ann Intern Med 1995;123:873-877
Web of Science | Medline
- Citing Articles (144)
Citing Articles
1
Jean M. Harnisch, Patricia H. Harnisch, David R. Harnisch. (2012) Family Medicine Obstetrics: Pregnancy and Nutrition. Primary Care: Clinics in Office Practice 39:1, 39-54
CrossRef2
Karin E. Fuchs, Mary E. D'Alton. 2012. Multiple Gestations. , 314-326.
CrossRef3
Edward R. Newton. 2012. Maternal Nutrition. , 4-22.
CrossRef4
Caren G. Solomon, Ellen W. Seely. (2011) Hypertension in Pregnancy. Endocrinology & Metabolism Clinics of North America 40:4, 847-863
CrossRef5
Viola Seravalli, Jason K. Baxter. 2011. Hypertensive disorders a a Hypertensive disorders of pregnancy include chronic hypertension, gestational hypertension, preeclampsia, HELLP syndrome, and eclampsia.. , 1-19.
CrossRef6
Pranom Buppasiri, Pisake Lumbiganon, Jadsada Thinkhamrop, Chetta Ngamjarus, Malinee Laopaiboon, Pranom Buppasiri. 2011. Calcium supplementation (other than for preventing or treating hypertension) for improving pregnancy and infant outcomes. .
CrossRef7
N. M. Talge, C. Holzman, P. K. Senagore, M. Klebanoff, R. Fisher. (2011) Biological indicators of the in-utero environment and their association with birth weight for gestational age. Journal of Developmental Origins of Health and Disease 2:05, 280-290
CrossRef8
J.-L. Schlienger. (2011) État des lieux des compléments alimentaires chez la femme enceinte. Médecine des Maladies Métaboliques 5:5, 521-532
CrossRef9
Seely, Ellen W., Ecker, Jeffrey, . (2011) Chronic Hypertension in Pregnancy. New England Journal of Medicine 365:5, 439-446
Full Text10
Karin Leslie, Basky Thilaganathan, Aris Papageorghiou. (2011) Early prediction and prevention of pre-eclampsia. Best Practice & Research Clinical Obstetrics & Gynaecology 25:3, 343-354
CrossRef11
S. Haché, L. Takser, F. LeBellego, H. Weiler, L. Leduc, J. C. Forest, Y. Giguère, A. Masse, B. Barbeau, J. Lafond. (2011) Alteration of calcium homeostasis in primary preeclamptic syncytiotrophoblasts: effect on calcium exchange in placenta. Journal of Cellular and Molecular Medicine 15:3, 654-667
CrossRef12
S. Hahn, C. Rusterholz, I. Hösli, O. Lapaire. (2011) Cell-free Nucleic Acids as Potential Markers for Preeclampsia. Placenta 32, S17-S20
CrossRef13
Sharon E. Maynard, S. Ananth Karumanchi. (2011) Angiogenic Factors and Preeclampsia. Seminars in Nephrology 31:1, 33-46
CrossRef14
Robert P. Heaney, Connie M. Weaver, Jeffrey Blumberg. (2011) EBN (Evidence-Based Nutrition) Ver. 2.0. Nutrition Today 46:1, 22-26
CrossRef15
Aamer Imdad, Afshan Jabeen, Zulfiqar A Bhutta. (2011) Role of calcium supplementation during pregnancy in reducing risk of developing gestational hypertensive disorders: a meta-analysis of studies from developing countries. BMC Public Health 11:Suppl 3, S18
CrossRef16
John M. Davison, Marshall D. Lindheimer. (2011) Pregnancy and Chronic Kidney Disease. Seminars in Nephrology 31:1, 86-99
CrossRef17
G Justus Hofmeyr, Theresa A Lawrie, Álvaro N Atallah, Lelia Duley, G Justus Hofmeyr. 2010. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. .
CrossRef18
Jeffrey Blumberg, Robert P Heaney, Michael Huncharek, Theresa Scholl, Meir Stampfer, Reinhold Vieth, Connie M Weaver, Steven H Zeisel. (2010) Evidence-based criteria in the nutritional context. Nutrition Reviews 68:8, 478-484
CrossRef19
Jay D. Iams, Vincenzo Berghella. (2010) Care for women with prior preterm birth. American Journal of Obstetrics and Gynecology 203:2, 89-100
CrossRef20
Audrey F. Saftlas, Elizabeth W. Triche, Hind Beydoun, Michael B. Bracken. (2010) Does Chocolate Intake During Pregnancy Reduce the Risks of Preeclampsia and Gestational Hypertension?. Annals of Epidemiology 20:8, 584-591
CrossRef21
Sharon Lewis, Robyn M. Lucas, Jane Halliday, Anne-Louise Ponsonby. (2010) Vitamin D deficiency and pregnancy: From preconception to birth. Molecular Nutrition & Food Researchn/a-n/a
CrossRef22
Megan L. Mulligan, Shaili K. Felton, Amy E. Riek, Carlos Bernal-Mizrachi. (2010) Implications of vitamin D deficiency in pregnancy and lactation. American Journal of Obstetrics and Gynecology 202:5, 429.e1-429.e9
CrossRef23
Paul Meria, Haider Hadjadj, Paul Jungers, Michel Daudon. (2010) Stone Formation and Pregnancy: Pathophysiological Insights Gained From Morphoconstitutional Stone Analysis. The Journal of Urology 183:4, 1412-1416
CrossRef24
Seema Jain, Priyamvada Sharma, Shobha Kulshreshtha, Govind Mohan, Saroj Singh. (2010) The Role of Calcium, Magnesium, and Zinc in Pre-Eclampsia. Biological Trace Element Research 133:2, 162-170
CrossRef25
G Justus Hofmeyr, Fiona M Smaill, Fiona M Smaill. 2010. Antibiotic prophylaxis for cesarean section. .
CrossRef26
Geralyn M. Lambert-Messerlian, Glenn E. Palomaki, Louis M. Neveux, Edward Chien, Alex Friedman, Karen Rosene-Montella, Meghan Hayes, Jacob A. Canick. (2009) Early onset preeclampsia and second trimester serum markers. Prenatal Diagnosis 29:12, 1109-1117
CrossRef27
Christopher T. Lang, Jay D. Iams. (2009) Goals and Strategies for Prevention of Preterm Birth: An Obstetric Perspective. Pediatric Clinics of North America 56:3, 537-563
CrossRef28
J Villar, M Purwar, M Merialdi, N Zavaleta, N thi Nhu Ngoc, J Anthony, A De Greeff, L Poston, A Shennan, . (2009) World Health Organisation multicentre randomised trial of supplementation with vitamins C and E among pregnant women at high risk for pre-eclampsia in populations of low nutritional status from developing countries. BJOG: An International Journal of Obstetrics & Gynaecology 116:6, 780-788
CrossRef29
Christina M. Scifres, Jay D. Iams, Mark Klebanoff, George A. Macones. (2009) Metaanalysis vs large clinical trials: which should guide our management?. American Journal of Obstetrics and Gynecology 200:5, 484.e1-484.e5
CrossRef30
Alexander M. Holston, Cong Qian, Kai F. Yu, Franklin H. Epstein, S. Ananth Karumanchi, Richard J. Levine. (2009) Circulating angiogenic factors in gestational proteinuria without hypertension. American Journal of Obstetrics and Gynecology 200:4, 392.e1-392.e10
CrossRef31
Gary Chan. 2009. Pregnancy. .
CrossRef32
Sophie Hawkesworth. (2009) Exploiting dietary supplementation trials to assess the impact of the prenatal environment on CVD risk. Proceedings of the Nutrition Society 68:01, 78
CrossRef33
Ashok Kumar, Salam Gyaneshwori Devi, Swaraj Batra, Chanchal Singh, Deepak Kumar Shukla. (2009) Calcium supplementation for the prevention of pre-eclampsia. International Journal of Gynecology & Obstetrics 104:1, 32-36
CrossRef34
P. Deruelle, J.-M. Girard, N. Coutty, D. Subtil. 2009. Prévention de la prééclampsie. , 57-66.
CrossRef35
Chun Lam, S. Ananth Karumanchi. 2009. Pregnancy and the Kidney. , 483-513.
CrossRef36
Baha M. Sibai, F. Gary Cunningham. 2009. Prevention of Preeclampsia and Eclampsia. , 213-225.
CrossRef37
Rocco C. Venuto, Marshall D. Lindheimer. 2009. Animal Models. , 169-188.
CrossRef38
E. Derbyshire, V. Costarelli. (2008) Dietary factors in the aetiology of postnatal depression. Nutrition Bulletin 33:3, 162-168
CrossRef39
Michael P. Carson, Deborah Ehrenthal. (2008) Medical Issues from Preconception Through Delivery: A Roadmap for the Internist. Medical Clinics of North America 92:5, 1193-1225
CrossRef40
R. B. Ness, J. Zhang, D. Bass, M. A. Klebanoff. (2008) Interactions between Smoking and Weight in Pregnancies Complicated by Preeclampsia and Small-for-Gestational-Age Birth. American Journal of Epidemiology 168:4, 427-433
CrossRef41
SHOBHA H. MEHTA. (2008) Nutrition and Pregnancy. Clinical Obstetrics and Gynecology 51:2, 409-418
CrossRef42
Manju Chandiramani, Andrew Shennan. (2008) Hypertensive disorders of pregnancy: a UK-based perspective. Current Opinion in Obstetrics and Gynecology 20:2, 96-101
CrossRef43
Jay D Iams, Roberto Romero, Jennifer F Culhane, Robert L Goldenberg. (2008) Primary, secondary, and tertiary interventions to reduce the morbidity and mortality of preterm birth. The Lancet 371:9607, 164-175
CrossRef44
Aaron B. Caughey, Kathryn A. Lee. (2007) CPAP for the prevention of pre-eclampsia: Is this a clinically promising intervention?. Sleep Medicine 9:1, 1-2
CrossRef45
Mounira Habli, Richard J. Levine, Cong Qian, Baha Sibai. (2007) Neonatal outcomes in pregnancies with preeclampsia or gestational hypertension and in normotensive pregnancies that delivered at 35, 36, or 37 weeks of gestation. American Journal of Obstetrics and Gynecology 197:4, 406.e1-406.e7
CrossRef46
Ramkrishna Mehendale, Judith Hibbard, Asgerally Fazleabas, Richard Leach. (2007) Placental angiogenesis markers sFlt-1 and PlGF: response to cigarette smoke. American Journal of Obstetrics and Gynecology 197:4, 363.e1-363.e5
CrossRef47
Emily Oken, Yi Ning, Sheryl L. Rifas-Shiman, Janet W. Rich-Edwards, Sjurdur F. Olsen, Matthew W. Gillman. (2007) Diet During Pregnancy and Risk of Preeclampsia or Gestational Hypertension. Annals of Epidemiology 17:9, 663-668
CrossRef48
L Michael Prisant. 2007. Nutritional Treatment of Blood Pressure. , 735-770.
CrossRef49
GJ Hofmeyr, L Duley, A Atallah. (2007) Dietary calcium supplementation for prevention of pre-eclampsia and related problems: a systematic review and commentary. BJOG: An International Journal of Obstetrics & Gynaecology 114:8, 933-943
CrossRef50
E. Ramsey Unal, Christopher J. Robinson, Donna D. Johnson, Eugene Y. Chang. (2007) Second-trimester angiogenic factors as biomarkers for future-onset preeclampsia. American Journal of Obstetrics and Gynecology 197:2, 211.e1-211.e4
CrossRef51
Steven J. Wagner, Snezana Barac, Vesna D. Garovic. (2007) Hypertensive Pregnancy Disorders: Current Concepts. The Journal of Clinical Hypertension 9:7, 560-566
CrossRef52
William J. Elliott. (2007) Systemic Hypertension. Current Problems in Cardiology 32:4, 201-259
CrossRef53
Luci Maria SantAna Dusse, Alan J. Cooper, Bashir A. Lwaleed. (2007) Thrombin activatable fibrinolysis inhibitor (TAFI): A role in pre-eclampsia?. Clinica Chimica Acta 378:1-2, 1-6
CrossRef54
Paula R. Trumbo, Kathleen C. Ellwood. (2007) Supplemental Calcium and Risk Reduction of Hypertension, Pregnancy-Induced Hypertension, and Preeclampsia: An Evidence-Based Review by the US Food and Drug Administration. Nutrition Reviews 65:2, 78-87
CrossRef55
Aba Barden-Maja, C. Jessica Dine, Laura M. Kosseim, Jodi Savitz, Daniel I. Steinberg. 2007. Selected Medical Problems Encountered During Pregnancy. , 444-491.
CrossRef56
2006. Dairy Foods and Hypertension. , 99-139.
CrossRef57
2006. Contribution of Dairy Foods to Health throughout the Life Cycle. , 339-399.
CrossRef58
William H. Frishman, Megan Veresh, Stacy J. Schlocker, Nergesh Tejani. (2006) Pathophysiology and medical management of systemic hypertension in preeclampsia. Current Hypertension Reports 8:6, 502-511
CrossRef59
Scott M Nelson, Ian A Greer. (2006) Hypertensive disorders of pregnancy: preventative-, immediate- and long-term management. Expert Review of Pharmacoeconomics & Outcomes Research 6:5, 541-554
CrossRef60
Levine, Richard J., Lam, Chun, Qian, Cong, Yu, Kai F., Maynard, Sharon E., Sachs, Benjamin P., Sibai, Baha M., Epstein, Franklin H., Romero, Roberto, Thadhani, Ravi, Karumanchi, S. Ananth, . (2006) Soluble Endoglin and Other Circulating Antiangiogenic Factors in Preeclampsia. New England Journal of Medicine 355:10, 992-1005
Full Text61
G Justus Hofmeyr, Álvaro N Atallah, Lelia Duley, G Justus Hofmeyr. 2006. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. .
CrossRef62
Jeyabalan, Arun, Caritis, Steve N., . (2006) Antioxidants and the Prevention of Preeclampsia — Unresolved Issues. New England Journal of Medicine 354:17, 1841-1843
Full Text63
Rumbold, Alice R., Crowther, Caroline A., Haslam, Ross R., Dekker, Gustaaf A., Robinson, Jeffrey S., . (2006) Vitamins C and E and the Risks of Preeclampsia and Perinatal Complications. New England Journal of Medicine 354:17, 1796-1806
Full Text64
Richard J. Levine, Cong Qian, Sharon E. Maynard, Kai F. Yu, Franklin H. Epstein, S. Ananth Karumanchi. (2006) Serum sFlt1 concentration during preeclampsia and mid trimester blood pressure in healthy nulliparous women. American Journal of Obstetrics and Gynecology 194:4, 1034-1041
CrossRef65
Michael Thomas, Steven M. Weisman. (2006) Calcium supplementation during pregnancy and lactation: Effects on the mother and the fetus. American Journal of Obstetrics and Gynecology 194:4, 937-945
CrossRef66
Young Mi Lee, Jane Cleary-Goldman, Mary E. D’Alton. (2006) Multiple Gestations and Late Preterm (Near-Term) Deliveries. Seminars in Perinatology 30:2, 103-112
CrossRef67
Barbara Luke. (2005) The evidence linking maternal nutrition and prematurity. Journal of Perinatal Medicine 33:6, 500-505
CrossRef68
Robert P. Heaney, Gloria A. Bachmann. (2005) Interpreting Studies of Nutritional Prevention: A Perspective Using Calcium as a Model. Journal of Women's Health 14:10, 889-897
CrossRef69
William H. Frishman, Stacy J. Schlocker, Ketti Awad, Nergesh Tejani. (2005) Pathophysiology and Medical Management of Systemic Hypertension in Pregnancy. Cardiology in Review 13:6, 274-284
CrossRef70
Stephen P. Emery, Richard J. Levine, Cong Qian, Marian G. Ewell, Lucinda J. England, Kai F. Yu, Patrick M. Catalano, . (2005) Twenty-four-hour urine insulin as a measure of hyperinsulinaemia/insulin resistance before onset of pre-eclampsia and gestational hypertension. BJOG: An International Journal of Obstetrics and Gynaecology 112:11, 1479-1485
CrossRef71
Kanchapan Sukonpan, Vorapong Phupong. (2005) Serum calcium and serum magnesium in normal and preeclamptic pregnancy. Archives of Gynecology and Obstetrics 273:1, 12-16
CrossRef72
Barbara Luke. (2005) Nutrition and Multiple Gestation. Seminars in Perinatology 29:5, 349-354
CrossRef73
Patricio López-Jaramillo, Ronald G García, Marcos López. (2005) Preventing pregnancy-induced hypertension: are there regional differences for this global problem?. Journal of Hypertension 23:6, 1121-1129
CrossRef74
Richard Lafayette. (2005) The kidney in preeclampsia. Kidney International 67:3, 1194-1203
CrossRef75
Baha Sibai, Gus Dekker, Michael Kupferminc. (2005) Pre-eclampsia. The Lancet 365:9461, 785-799
CrossRef76
Lauren A. Beste, Lucinda J. England, Enrique F. Schisterman, Cong Qian, Kai F. Yu, Richard J. Levine. (2005) Pregnancy outcomes in smokers who develop pre-eclampsia. Paediatric and Perinatal Epidemiology 19:1, 12-18
CrossRef77
JF Ludvigsson, J Ludvigsson. (2004) Milk consumption during pregnancy and infant birthweight. Acta Paediatrica 93:11, 1474-1478
CrossRef78
J K. Phillips, Ira M. Bernstein, J A. Mongeon, G J. Badger. (2004) Seasonal Variation in Preeclampsia Based on Timing of Conception. Obstetrics & Gynecology 104:5, Part 1, 1015-1020
CrossRef79
2004. Calcium. .
CrossRef80
Haraldur M. Gudnasson, Mariusz Dubiel, Saemundur Gudmundsson. (2004) Preeclampsia – abnormal uterine artery Doppler is related to recurrence of symptoms during the next pregnancy. Journal of Perinatal Medicine 32:5, 400-403
CrossRef81
O Burger, E Pick, J Zwickel, M Klayman, H Meiri, R Slotky, S Mandel, L Rabinovitch, Y Paltieli, A Admon, R Gonen. (2004) Placental protein 13 (PP-13): effects on cultured trophoblasts, and its detection in human body fluids in normal and pathological pregnancies. Placenta 25:7, 608-622
CrossRef82
Dana P. Damron, Beth A. Bouchard, Robert E. Shapiro, Adrienne L. Schonberg, Ira M. Bernstein. (2004) Platelet Activation, Sympathetic Tone, and Plasma Volume in Nulligravid Women of Reproductive Age. Obstetrics & Gynecology 103:5, Part 1, 931-936
CrossRef83
Richard J Levine, Cong Qian, Erik S LeShane, Kai F Yu, Lucinda J England, Enrique F Schisterman, Tuangsit Wataganara, Roberto Romero, Diana W Bianchi. (2004) Two-stage elevation of cell-free fetal DNA in maternal sera before onset of preeclampsia. American Journal of Obstetrics and Gynecology 190:3, 707-713
CrossRef84
Levine, Richard J., Maynard, Sharon E., Qian, Cong, Lim, Kee-Hak, England, Lucinda J., Yu, Kai F., Schisterman, Enrique F., Thadhani, Ravi, Sachs, Benjamin P., Epstein, Franklin H., Sibai, Baha M., Sukhatme, Vikas P., Karumanchi, S. Ananth, . (2004) Circulating Angiogenic Factors and the Risk of Preeclampsia. New England Journal of Medicine 350:7, 672-683
Full Text85
Solomon, Caren G., Seely, Ellen W., . (2004) Preeclampsia — Searching for the Cause. New England Journal of Medicine 350:7, 641-642
Full Text86
Tania Haddad. (2003) Update on Pre-eclampsia. International Anesthesiology Clinics 40:4, 115-135
CrossRef87
Benoit Bailey. (2003) Are there teratogenic risks associated with antidotes used in the acute management of poisoned pregnant women?. Birth Defects Research Part A: Clinical and Molecular Teratology 67:2, 133-140
CrossRef88
John S. Lam, Mantu Gupta. (2002) Tips and Tricks for the Management of Retained Ureteral Stents. Journal of Endourology 16:10, 733-741
CrossRef89
GJ Hofmeyr, AN Atallah, L Duley, G Justus Hofmeyr. 2002. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. .
CrossRef90
G Justus Hofmeyr, Fiona M Smaill, Fiona M Smaill. 2002. .
CrossRef91
Per Magnus, Anne Eskild. (2001) Seasonal variation in the occurrence of pre-eclampsia. BJOG: An International Journal of Obstetrics and Gynaecology 108:11, 1116-1119
CrossRef92
David Weismiller, Kathryn Kolasa. 2001. Nutrition during Pregnancy and Lactation. .
CrossRef93
L Michael Prisant. 2001. Nutritional Treatment of Blood Pressure. .
CrossRef94
Adrianne Bendich. (2001) Micronutrients in women’s health and immune function. Nutrition 17:10, 858-867
CrossRef95
MADDALENA SMID, ANTONIA VASSALLO, FIORENZA LAGONA, LUCA VALSECCHI, LUCIA MANISCALCO, LUANA DANTI, ANDREA LOJACONO, AUGUSTO FERRARI, MAURIZIO FERRARI, LAURA CREMONESI. (2001) Quantitative Analysis of Fetal DNA in Maternal Plasma in Pathological Conditions Associated with Placental Abnormalities. Annals of the New York Academy of Sciences 945:1, 132-137
CrossRef96
Nigel M Page, C Fred Kemp, Philip J Lowry. (2001) Emerging molecular targets for the treatment of pre-eclampsia. Expert Opinion on Therapeutic Targets 5:3, 395-413
CrossRef97
Patricia Johnston. 2001. Vegetarian Diets in Pregnancy and Lactation. , 195-219.
CrossRef98
Rory Collins, Stephen MacMahon. (2001) Reliable assessment of the effects of treatment on mortality and major morbidity, I: clinical trials. The Lancet 357:9253, 373-380
CrossRef99
SS Iyengar. (2001) Pre-eclampsia. The Lancet 357:9252, 312-313
CrossRef100
G. Carroli, C. Rooney, J. Villar. (2001) How effective is antenatal care in preventing maternal mortality and serious morbidity? An overview of the evidence. Paediatric and Perinatal Epidemiology 15:s1, 1-42
CrossRef101
G. Carroli, C. Rooney, J. Villar. (2001) How effective is antenatal care in preventing maternal mortality and serious morbidity? An overview of the evidence. Paediatric and Perinatal Epidemiology 15:1, 1-42
CrossRef102
Gus Dekker, Baha Sibai. (2001) Primary, secondary, and tertiary prevention of pre-eclampsia. The Lancet 357:9251, 209-215
CrossRef103
James J Walker. (2000) Pre-eclampsia. The Lancet 356:9237, 1260-1265
CrossRef104
V D Garovic. (2000) Hypertension in pregnancy: diagnosis and treatment.. Mayo Clinic Proceedings 75:10, 1071-1076
CrossRef105
M.S. Kramer, L. Seguin, J. Lydon, L. Goulet. (2000) Socio-economic disparities in pregnancy outcome: why do the poor fare so poorly?. Paediatric and Perinatal Epidemiology 14:3, 194-210
CrossRef106
Ann Prentice. (2000) C
ALCIUM IN PREGNANCY AND LACTATION . Annual Review of Nutrition 20:1, 249-272
CrossRef107
MA Brown, WM Hague, J Higgins, S Lowe, L McCowan, J Oats, MJ Peek, JA Rowan, BNJ Walters. (2000) The detection, investigation and management of hypertension in pregnancy: full consensus statement. The Australian and New Zealand Journal of Obstetrics and Gynaecology 40:2, 139-155
CrossRef108
Patricio López-Jaramillo. (2000) Calcium, nitric oxide, and preeclampsia. Seminars in Perinatology 24:1, 33-36
CrossRef109
Klaus Kisters, Martin Hausberg, Markus Kosch. (2000) Reduced intestinal epithelial cell brush border membrane calcium transport in spontaneously hypertensive rats. Journal of Hypertension 18:5, 643
CrossRef110
E. S. Venkatraman, Colin B. Begg. (1999) Properties of A Nonparametric Test for Early Comparison of Treatments in Clinical Trials in the Presence of Surrogate Endpoints. Biometrics 55:4, 1171-1176
CrossRef111
Roberta Shear, Line Leduc, Evelyne Rey, Jean-Marie Moutquin. (1999) Hypertension in pregnancy: New recommendations for managemen. Current Hypertension Reports 1:6, 529-539
CrossRef112
Jun Zhang, Mark A. Klebanoff, Richard J. Levine, Mala Puri, Patricia Moyer. (1999) The puzzling association between smoking and hypertension during pregnancy. American Journal of Obstetrics and Gynecology 181:6, 1407-1413
CrossRef113
Michael L. Power, Robert P. Heaney, Heidi J. Kalkwarf, Roy M. Pitkin, John T. Repke, Reginald C. Tsang, Jay Schulkin. (1999) The role of calcium in health and disease. American Journal of Obstetrics and Gynecology 181:6, 1560-1569
CrossRef114
1999. Contribution of Milk and Milk Products to Health Throughout the Life Cycle. .
CrossRef115
ERROL R. NORWITZ, JULIAN N. ROBINSON, JOHN T. REPKE. (1999) Prevention of Preeclampsia: Is It Possible?. Clinical Obstetrics and Gynecology 42:3, 436
CrossRef116
Priscilla LeMone. (1999) Vitamins and Minerals. Journal of Obstetric, Gynecologic, <html_ent glyph="@amp;" ascii="&"/> Neonatal Nursing 28:5, 520-533
CrossRef117
WILLIAM C. MABIE. (1999) Management of Acute Severe Hypertension and Encephalopathy. Clinical Obstetrics and Gynecology 42:3, 519
CrossRef118
Ravi Thadhani, Meir J Stampfer, Lisa Chasan-Taber, Walter C Willett, Gary C Curhan. (1999) A prospective study of pregravid oral contraceptive use and risk of hypertensive disorders of pregnancy. Contraception 60:3, 145-150
CrossRef119
Elaine DiFederico, Olga Genbacev, Susan J. Fisher. (1999) Preeclampsia Is Associated with Widespread Apoptosis of Placental Cytotrophoblasts within the Uterine Wall. The American Journal of Pathology 155:1, 293-301
CrossRef120
H.J. Singh, N.H. Mohammad, A. Nila. (1999) Serum calcium and parathormone during normal pregnancy in Malay women. The Journal of Maternal-Fetal Medicine 8:3, 95-100
CrossRef121
Dilly O.C. Anumba, Stephen C. Robson. (1999) Management of pre-eclampsia and haemolysis, elevated liver enzymes, and low platelets syndrome. Current Opinion in Obstetrics and Gynaecology 11:2, 149-156
CrossRef122
Rebecca DerSimonian. (1999) Conference on meta-analysis in the design and monitoring of clinical trials by N. Geller, L. Freedman, Y. J. Lee and R. DerSimonian (eds),Statistics in Medicine,15, 1233-1324 (1996). Statistics in Medicine 18:6, 753-754
CrossRef123
Andrea G. Witlin. (1999) Counseling for women with preeclampsia or eclampsia. Seminars in Perinatology 23:1, 91-98
CrossRef124
Caroline A. Crowther, Janet E. Hiller, Brian Pridmore, Robert Bryce, Paul Duggan, William M. Hague, Jeffrey S. Robinson. (1999) Calcium Supplementation In Nulliparous Women For The Prevention Of Pregnancy-Induced Hypertension, Preeclampsia And Preterm Birth: An Australian Randomized Irial. Australian and New Zealand Journal of Obstetrics and Gynaecology 39:1, 12-18
CrossRef125
Farid Mattar, Baha M. Sibai. (1999) Prevention of preeclampsia. Seminars in Perinatology 23:1, 58-64
CrossRef126
Mark A Brown, Judith A Whitworth. (1999) Management of Hypertension in Pregnancy. Clinical and Experimental Hypertension 21:5-6, 907-916
CrossRef127
Carol West Suitor. (1999) Nutrition for Women in their Childbearing Years: A Review of the Literature and a Summary of Expert Recommendations. Nutrition in Clinical Care 2:1, 11-45
CrossRef128
Metin Gulmezoglu, Jose Villar, Justus Hofmeyr, Lelia Duley, Jose M. Belizan. (1998) Randomised trials in maternal and perinatal medicine: global partnerships are the way forward. BJOG: An International Journal of Obstetrics and Gynaecology 105:12, 1244-1247
CrossRef129
Baha M. Sibai. (1998) Prevention of preeclampsia: A big disappointment. American Journal of Obstetrics and Gynecology 179:5, 1275-1278
CrossRef130
José M. Belizán. (1998) Obstetrics and gynaecology, and women's health. BJOG: An International Journal of Obstetrics & Gynaecology 105:11, 1237-1237
CrossRef131
Gary M. Joffe, Joy R. Esterlitz, Richard J. Levine, John D. Clemens, Marian G. Ewell, Baha M. Sibai, Patrick M. Catalano. (1998) The relationship between abnormal glucose tolerance and hypertensive disorders of pregnancy in healthy nulliparous women. American Journal of Obstetrics and Gynecology 179:4, 1032-1037
CrossRef132
Howard Cuckle, Indera Sehmi, Richard Jones. (1998) Maternal serum inhibin A can predict pre-eclampsia. BJOG: An International Journal of Obstetrics and Gynaecology 105:10, 1101-1103
CrossRef133
Caroline H Damsky, Susan J Fisher. (1998) Trophoblast pseudo-vasculogenesis: faking it with endothelial adhesion receptors. Current Opinion in Cell Biology 10:5, 660-666
CrossRef134
Jose Villar, A. Metin Gulmezoglu, Mercedes de Onis. (1998) Nutritional and Antimicrobial Interventions to Prevent Preterm Birth. Obstetrical & Gynecological Survey 53:9, 575-585
CrossRef135
Goldenberg, Robert L., Rouse, Dwight J., . (1998) Prevention of Premature Birth. New England Journal of Medicine 339:5, 313-320
Full Text136
JOSEPH W. HOGAN, JEFFREY F. PEIPERT. (1998) Power and Sample Size. Clinical Obstetrics and Gynecology 41:2, 257-266
CrossRef137
John R. Higgins, Shaun P. Brennecke. (1998) Pre-eclampsia - still a disease of theories?. Current Opinion in Obstetrics and Gynaecology 10:2, 129-133
CrossRef138
Carl J. Saphier, John T. Repke. (1998) Hemolysis, elevated liver enzymes, and low platelets (HELLP) syndrome: a review of diagnosis and management. Seminars in Perinatology 22:2, 118-133
CrossRef139
Cassandra E Henderson, Dennis Ownby, Mark Klebanoff, Richard J Levine. (1998) Stability of immunoglobulin E (IgE) in stored obstetric sera. Journal of Immunological Methods 213:1, 99-101
CrossRef140
B. Bassaw, S. Roopnarinesingh, A. Roop. (1998) Prevention of hypertensive disorders of pregnancy. Journal of Obstetrics & Gynaecology 18:2, 123-126
CrossRef141
(1998) Review articles. Journal of Perinatal Medicine 26:5, 337-353
CrossRef142
Joseph Lau, John PA Ioannidis, Christopher H Schmid. (1998) Summing up evidence: one answer is not always enough. The Lancet 351:9096, 123-127
CrossRef143
B.M. Sibai, M. Ewell, R.J. Levine, M.A. Klebanoff, J. Esterlitz, P.M. Catalano, R.L. Goldenberg, G. Joffe. (1997) Risk factors associated with preeclampsia in healthy nulliparous women. American Journal of Obstetrics and Gynecology 177:5, 1003-1010
CrossRef144
Roberts, James M., . (1997) Prevention or Early Treatment of Preeclampsia. New England Journal of Medicine 337:2, 124-125
Full Text
